Dechra Veterinary Products, LLC

Piedmont Animal Health Inc.

Ciba-geigy Corporation

Bayer Healthcare LLC

Idexx Laboratories, Inc.

Novartis Animal Health Us, Inc.

Idexx Pharmaceuticals, Inc.

Bayer B.v.

Douglas Hepler

Gail Dempsey

Neil E Paulsen

Michael S Daniel

Dorothea Erxleben

Tiffany G Tomlinson

Raymond Petzold

Roland H Johnson

William R Campbell

Kenneth A Larson

Roland Johnson

Steven Craig Parks

Philip Anthony Lowndes

Michael Kelly

Sharron H Barnett

Manfred Boger

Kathleen G Palma

Stefan Kemmethm&uuml;ller

Stefan Kemmethmuller

Ray Petzold

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and/or clotrimazole and dexamethasone.

OTIC formulations, methods and devices

Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Injectable antibiotic formulations and use thereof

Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for subcutaneous injection.

Long-acting injectable formulations and use thereof

Otic formulations, methods and devices

A single-dose oral formulation of spinosad and lufenuron and methods for its use in the extended control of a flea infestation on a domestic animal such as a dog without emesis.

Combinations of acaricides and insect growth regulators for control of fleas without emesis in animals

Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for subcutaneous injection, in particular analgesics such as buprenorphine.

Long-acting non-aqueous injectable formulations and use thereof

Pharmaceutically acceptable single parasiticidal agent compositions of imidacloprid for oral delivery to mammals to systemically control targeted blood-sucking or blood-consuming parasites, such as fleas, ticks and certain species of helminthes and scabies.

Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent

Methods for treating and preventing otitis externa with a course of treatment consisting of as little as a single dose are provided. The methods are practiced by topical administration of compositions having a lipid carrier, such as liposomes and non-vesicular lipids, to the outer ear canal. Such compositions lack viscocity-enhancing celluloses or adhesives, and are preferably not in the form of a gel. Active agents useful for treating pain, inflammation, fungal or parasitic infestation and/or infections in the outer ear are co-administered in or with the composition.

Methods and compositions for rapid treatment of otitis externa

A liposome formulation containing about 1% diclofenac is an effective topical anti-inflammatory topical treatment for lameness in horses. More particularly it has been discovered that a formulation containing vitamin E, phospholipid and diclofenac salt such as the sodium or potassium salt is a highly effective topical anti-inflammatory formulation that is particularly effective in treating lameness in horses.

Liposomal analgesic formulation and use

Growing community of inventors

Greensboro, NC, United States of America

Douglas Hepler